<em id="uwvqh"><samp id="uwvqh"></samp></em>

FCPR03 NEW

Price	$48	$69	$118
Package	1mg	2mg	5mg

Min. Order:
Supply Ability:	10g
Update Time:	2024-11-11

Product Details

Product Name: FCPR03	CAS No.: 1917347-65-9
Purity: 100.00%	Supply Ability: 10g
Release date: 2024/11/11

Product Introduction

Bioactivity

名稱	FCPR03
描述	FCPR03 is a selective inhibitor of phosphodiesterase 4 (PDE4) with IC50s of 31 nM, 47 nM, and 60 nM for PDE4B1, PDE4D7, and PDE4 catalytic domain, respectively. FCPR03 has neuroprotective, anti-inflammatory, and antidepressant-like effects.
體外活性	FCPR03 displays at least 2100-fold selectivity over other PDEs (PDE1-3 and PDE5-11). In HT-22 cells, FCPR03 (5, 10, and 20 μM) increases cell viability under the oxygen-glucose deprivation (OGD) induced condition in a dose-dependent manner. FCPR03 (20 μM) increases the levels of phosphorylated AKT, GSK-3β, and β-catenin. FCPR03 (20 μM) protects against OGD-induced cellular apoptosis in both HT-22 cells and cortical neurons. The levels of mitochondrial membrane potential (MMP) and ROS are restored by FCPR03. FCPR03 (10 μM) shows significant protective effects[2].
體內(nèi)活性	In adult male Sprague-Dawley rats following cerebral ischemia-reperfusion, FCPR03 increases the levels of phosphorylated AKT, GSK3β and β-catenin within the ischemic penumbra. In rats following MCAO, FCPR03 (1.25, 2.5, 5 mg/kg; i.p.) reduces the infarct volume and improves neurobehavioral outcomes[2].
存儲條件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	DMSO : 95 mg/mL (317.40 mM), Sonication is recommended.
關(guān)鍵字	antidepressant-like \| PDE4B1 \| PDE4D7 \| FCPR-03 \| PDE4 \| neuroprotective \| ischemic \| AKT \| GSK3β \| FCPR 03 \| FCPR03 \| inhibit \| anti-inflammatory \| Phosphodiesterase (PDE) \| β-catenin \| Inhibitor \| stroke
相關(guān)產(chǎn)品	Theophylline monohydrate \| Diphylline \| Acefylline \| Roflumilast \| Theobromine \| Apremilast \| Isoprenaline hydrochloride \| Indomethacin \| Icariin \| Theophylline \| Vardenafil hydrochloride \| Doxofylline
相關(guān)庫	經(jīng)典已知活性庫 \| 抗抑郁癥化合物庫 \| 抑制劑庫 \| 神經(jīng)保護(hù)化合物庫 \| 代謝化合物庫 \| 抗衰老化合物庫 \| 已知活性化合物庫

Company Profile Introduction

Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.